{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "15963880",
  "DateCompleted": {
    "Year": "2005",
    "Month": "09",
    "Day": "08"
  },
  "DateRevised": {
    "Year": "2005",
    "Month": "06",
    "Day": "20"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0891-5520",
      "JournalIssue": {
        "Volume": "19",
        "Issue": "2",
        "PubDate": {
          "Year": "2005",
          "Month": "Jun"
        }
      },
      "Title": "Infectious disease clinics of North America",
      "ISOAbbreviation": "Infect Dis Clin North Am"
    },
    "ArticleTitle": "Developments in STD/HIV interactions: the intertwining epidemics of HIV and HSV-2.",
    "Pagination": {
      "StartPage": "415",
      "EndPage": "425",
      "MedlinePgn": "415-25"
    },
    "Abstract": {
      "AbstractText": [
        "Antiviral agents aimed at treating HSV-2 chronically infected individuals have proven to be effective in the prevention of symptomatic genital herpes and the reduction of viral shedding. These agents play a key role in current HIV prevention trials that will assess the role of suppression of HSV-2 infection on the risk for HIV acquisition and transmission. An added clinical benefit of treating HSV-2/HIV-coinfected individuals is the potential survival benefit, as suggested by earlier studies and by the recent findings that HSV-2/HIV dually infected individuals have higher viral loads. The results of the current HSV-2 suppression trials may provide additional tools to fight the global spread of HIV infection. Treatment of HSV-2/HIV dually infected individuals may prove to be a low-cost intervention to improve clinical outcomes and delay the need for antiretroviral therapy."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Infectious Diseases, Johns Hopkins University School of Medicine, Ross 1159, 720 Rutland Avenue, Baltimore, MD 21205, USA. sreynol6@jhmi.edu"
          }
        ],
        "LastName": "Reynolds",
        "ForeName": "Steven J",
        "Initials": "SJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Quinn",
        "ForeName": "Thomas C",
        "Initials": "TC"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Infect Dis Clin North Am",
    "NlmUniqueID": "8804508",
    "ISSNLinking": "0891-5520"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "virology"
      ],
      "DescriptorName": "Disease Susceptibility"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "epidemiology",
        "transmission",
        "virology"
      ],
      "DescriptorName": "HIV Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "HIV-1"
    },
    {
      "QualifierName": [
        "complications",
        "drug therapy",
        "epidemiology"
      ],
      "DescriptorName": "Herpes Genitalis"
    },
    {
      "QualifierName": [
        "pathogenicity"
      ],
      "DescriptorName": "Herpesvirus 2, Human"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prevalence"
    }
  ],
  "NumberOfReferences": "42"
}